ArticleAustin neurology & neurosciences2017
BDNF in the Aged Brain: Translational Implications for Parkinson's Disease.
Article in Austin neurology & neurosciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The winter is coming: seasonal variations in BDNF levels among older adults in a high-latitude region - a preliminary study.Frontiers in psychiatry · 2025Article
- Advancing age and the rs6265 BDNF SNP are permissive to graft-induced dyskinesias in parkinsonian rats.NPJ Parkinson's disease · 2024Article
- Brain-Derived Neurotrophic Factor - The Protective Agent Against Neurological Disorders.CNS & neurological disorders drug targets · 2024Article
- Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine.Experimental neurology · 2023Article
- Cellular and Molecular Mechanisms of Vestibular Ageing.Journal of clinical medicine · 2023Review
- New Frontiers in Neurodegeneration and Regeneration Associated with Brain-Derived Neurotrophic Factor and the rs6265 Single Nucleotide Polymorphism.International journal of molecular sciences · 2022Review
- Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach.Biomaterials · 2021Article
- MiR-193b deregulation is associated with Parkinson's disease.Journal of cellular and molecular medicine · 2021Article
- Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Article
- Insights into the Effects of Mesenchymal Stem Cell-Derived Secretome in Parkinson's Disease.International journal of molecular sciences · 2020Review
- The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders.Expert review of neurotherapeutics · 2020Review
- Psychological distress and lack of PINK1 promote bioenergetics alterations in peripheral blood mononuclear cells.Scientific reports · 2020Article
- Effects of the probiotic formulation SLAB51 inAging · 2020Article
- Cell therapy for Parkinson's disease: Why it doesn't work every time.Movement disorders : official journal of the Movement Disorder Society · 2019Article
- Diet in Parkinson's Disease: Critical Role for the Microbiome.Frontiers in neurology · 2019Review
- In silico analysis of the V66M variant of human BDNF in psychiatric disorders: An approach to precision medicine.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Brain Derived Neurotrophic Factor (BDNF) is a member of the neurotrophin family of secreted growth factors. BDNF signaling is known to exert both chronic, pro-survival effects related to gene expression and protein synthesis ("canonical signaling"), and acute effects as a modulator of neurotransmission ("non-canonical signaling"). BDNF has received a great deal of attention for its role in neurodegenerative diseases including Huntington's Disease (HD), Alzheimer's Disease (AD), and Parkinson's Disease (PD) and has been extensively reviewed elsewhere in this regard (e.g., [1-6]). However aging-related changes in BDNF function and expression have been studied only rarely, with the majority of studies characterizing changes in structures such as the hippocampus and neocortex. In this review, we attempt to briefly summarize the extent of the existing literature on age-related BDNF changes, and discuss the relevance of these changes as a factor potentially impacting therapeutics in aged parkinsonian subjects.
Indexed as
Identifiers
29726549PMC5929154What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.